Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Retinopathy, Diabetic Clear all
Active, not recruiting Phase 3 Interventional

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

NCT03811561
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Coronado, California + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

NCT03197870
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
AKB-9778, Placebo
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Squalamine for the Treatment in Proliferative Diabetic Retinopathy

NCT01769183
View directory record Official record
Conditions
Retinal Neovascularization
Interventions
Squalamine Lactate ophthalmic solution 0.2%
Drug
Lead sponsor
Elman Retina Group
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Jul 23, 2026, 6:28 PM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Diabetic Macular Edema

NCT00959725
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Infliximab (intravitreal, 2.0mg/0.05ml)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2009 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

NCT04612868
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy
Interventions
AEYE Software Device
Device
Lead sponsor
AEYE Health Inc
Industry
Eligibility
22 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Results available

OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits

NCT01875783
View directory record Official record
Conditions
Diabetes, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
OCT imaging
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Wellfleet, Massachusetts • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

NCT04265261
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Placebo, RG7774
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Jul 23, 2026, 6:28 PM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00287651
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Pulsatile IV Insulin, Effects of Pulsatile IV Insulin on Diabetic Retinopathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

NCT01331005
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
nepafenac 0.1% drops, Nepafenac Vehicle
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 23, 2026, 6:28 PM EDT
Not listed Not applicable Interventional

Prospective Study of Adjunctive Carotenoids Plus Anti-oxidants in Anti-VEGF Treated Diabetic Macular Edema

NCT03866005
View directory record Official record
Conditions
Center-involved Diabetic Macular Edema (CI-DME)
Interventions
Diabetes Visual Function Study (DiVFuSS) softgels, canola oil placebo softgels, 2 per day
Dietary Supplement · Other
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Olympia, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 4 Interventional

Ocular Safety and Usability Study for FYB203 PFS

NCT06708637
View directory record Official record
Conditions
Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Interventions
FYB203 2 mg (0.05 mL of 40 mg/mL)
Drug
Lead sponsor
Formycon AG
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Campbell, California • Long Beach, California • Redlands, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 23, 2026, 6:28 PM EDT
Active, not recruiting Phase 4 Interventional

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Aflibercept 8mg
Drug
Lead sponsor
Edward Wood, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Austin, Texas • Bellaire, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy

NCT02863354
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept
Drug
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Houston, Texas • Katy, Texas • Kingwood, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jul 23, 2026, 6:28 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Arcadia, California • Huntington Beach, California • Modesto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 1 Interventional

Pilot Study of Laser Photocoagulation Therapy for Diabetic Macular Edema

NCT00069056
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Laser Treatment
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.

NCT03238963
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 1467335, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Dothan, Alabama • Phoenix, Arizona • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Jul 23, 2026, 6:28 PM EDT
Terminated Not applicable Interventional Results available

SD-OCT Angiography

NCT02510885
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
AngioVue SD-OCT
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Jul 23, 2026, 6:28 PM EDT
Not listed Phase 2 Interventional

Analysis of Aqueous and Vitreous Humor

NCT02067013
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy, Macular Degeneration, Macular Hole, Neovascular Glaucoma
Interventions
Ranibizumab, No Ranibizumab
Drug · Other
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 4 Interventional Results available

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

NCT02503540
View directory record Official record
Conditions
Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions
Aflibercept
Drug
Lead sponsor
Justis Ehlers
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 23, 2026, 6:28 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA VS. PREDNISOLONE ACETATE 1% Macular Edema With Diabetic Retinopathy After Cataract Surgery

NCT04362241
View directory record Official record
Conditions
Retinopathy, Diabetic
Interventions
Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
Drug
Lead sponsor
Ophthalmic Consultants of the Capital Region
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Troy, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional

The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy

NCT01364129
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ophthalmic Telemedicine
Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Wichita, Kansas • Pendleton, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers

NCT02823600
View directory record Official record
Conditions
Kidney Failure, Chronic, Eye Diseases, Diabetic Retinopathy
Interventions
RetinaVue 100 camera
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

NCT04424290
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
BI 764524, Sham control of BI 764524
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Jul 23, 2026, 6:28 PM EDT
Completed Phase 2 Interventional Results available

ADVM-022 Intravitreal Gene Therapy for DME

NCT04418427
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 23, 2026, 6:28 PM EDT